Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
8/21/2024 | $92.00 → $94.00 | Perform | Oppenheimer | |
8/15/2024 | $76.00 → $90.00 | Sell → Neutral | UBS | |
8/14/2024 | $100.00 → $85.00 | Buy → Hold | Stifel | |
6/28/2024 | $96.00 | Outperform | Robert W. Baird | |
5/30/2024 | $83.00 | Sell | Goldman | |
4/11/2024 | $88.00 | Buy | CL King | |
2/7/2024 | $87.00 | Neutral | BofA Securities | |
12/21/2023 | $100.00 | Hold → Buy | Canaccord Genuity |
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
S-8 - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
IRANNOTICE - Medtronic plc (0001613103) (Filer)
Customers are being notified of the importance of checking built-in alerts and alarms for battery status and to contact Medtronic for pump replacement if affected by this issue GALWAY, Ireland, Oct. 4, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump. Medtronic began investigating this issue upon receiving customer reports of shortened battery life and a comprehe
Dallas, Texas, Oct. 01, 2024 (GLOBE NEWSWIRE) -- GI Alliance, the nation's leading network of managed gastroenterology practices, is proud to announce a strategic and collaborative relationship with Medtronic, a global leader in healthcare technology, to deliver the opportunity to utilize Medtronic's GI Genius™ intelligent endoscopy module to the Alliance's more than 400 site locations. After a thorough evaluation of AI technologies, the GI Alliance Innovation Committee leveraged GI Genius™ as part of an internal post-marketing analysis, which included a trial at three of the Alliance's member networks and demonstrated a numerically significant improvement in polyp detection rates. This gr
APHRS: New data confirm robust long-term durability and highly efficient procedure performed without fluoroscopySuccessful launch in Japan follows recent reimbursement approval Approvals across APAC including China and Australia broaden reach for patientsGALWAY, Ireland and SYDNEY, Sept. 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect™ Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstr
PaceMate®, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from Medtronic (NYSE:MDT) This strategic move significantly expands PaceMate's reach globally, adding nearly 1,000 clinic locations worldwide. This further enhances PaceMate's ability to provide the leading and most comprehensive cardiac remote monitoring solution, continuing its position as the preferred partner in advanced cardiac data management. "After a comprehensive evaluation, we are confident PaceMate is the best organization to service Paceart customers and their future cardiac data workflow needs," said Kwe
Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation GALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024. Key Highlights Revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organicGAAP diluted earnings per share (EPS) of $0.80; non-GAAP diluted EPS of $1.23Company increases FY25 organic revenue growth and EPS guidanceMultiple franchises deliv
GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on October 11, 2024, to shareholders of record at the close of business on September 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, h
Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of their health metrics. Also Read: Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits. Ford projected that Lingo could become a multi-billion-dollar product, although it is still in its nascent stage. Lingo, an over-the-counter device, is scheduled to launch this year alongside Libre Rio, which received FDA clearance last month. Abbott’s consumer bi
RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:MDT) with a Sector Perform and maintains $92 price target.
Medtronic (NYSE:MDT) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 5 0 2 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 1 3 0 2 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.25, a high estimate of $105.00, and a low estimate of $76.00. This current average represents a 1.79% decrease from the previ
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
3 - Medtronic plc (0001613103) (Issuer)
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
SAN DIEGO, June 20, 2024 /PRNewswire/ -- Sempra (NYSE:SRE) (BMV:SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20, 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE:MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry. "Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infras
SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven
Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit
Oppenheimer reiterated coverage of Medtronic with a rating of Perform and set a new price target of $94.00 from $92.00 previously
UBS upgraded Medtronic from Sell to Neutral and set a new price target of $90.00 from $76.00 previously
Stifel downgraded Medtronic from Buy to Hold and set a new price target of $85.00 from $100.00 previously
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)